AB1064 THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND CENTRAL SENSITIZATION IN SPONDYLOARTHROPATHY PATIENTS RECEIVING BIOLOGICAL TREATMENT
Authors: N. Öz, A. Ozer, M. T. Duruöz
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Spondyloarthritis (SpA) is a chronic systemic inflammatory disease. Most patients with SpA complain of chronic pain during the course of the disease. Chronic pain can be explained by central sensitization (SS). <h3>Objectives</h3> Our aim was to investigate the relationship between disease activity and SS in patients with SpA receiving biologic therapy. <h3>Methods</h3> 92 patients with SpA who met the ASAS criteria were included in this <i>retrospective</i> study. Demographic characteristics of patients, comorbidities, drug treatments used, Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Functional Index (BASFI), visual analog scale (VAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Index (ASDAS-CRP), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), Central Sensitization Scale (SSS) were calculated. Patients were divided into 2 groups according to BASDAI score &lt;4 low disease activity and ≥4 high disease activity. All parameters between groups were compared. The correlation between the patients' SSQ scores and their BASDAI and ASDAS-CRP scores was analyzed. In addition, ROC analysis was performed to estimate the disease activity of the SS value and the optimal threshold value was determined. <h3>Results</h3> The proportion of patients with high disease activity was 41.3% (n=38 patients). There was no statistically significant difference between the low disease activity (group 1) and high disease activity (group 2) groups in terms of age, gender, body mass index, comorbid diseases, and the medical treatment (NSAID, steroid, methotrexate, sulfasalazine). There was no statistically significant difference between the groups in ESH, CRP and vitamin D levels. SS, MASES, BASFI, and ASDAS-CRP were found to be significantly higher in group 2 patients, respectively (40.87 ± 12.26 vs. 26.78 ± 11.81, p &lt; 0.001; 6.32 ± 3.60 vs. 3.69 ± 3.05, p = 0.001; 5.77 ± 2.12 against 2.80 ± 1.33, p &lt; 0.001, 3.35 ± 0.70 versus 2.43 ± 0.45, p &lt; 0.001). A moderate correlation was found between the SS scale and ASDAS-CRP (r:0.421; p&lt;0.001) and BASDAI (r:0.581; p&lt;0.001). ROC curve analysis showed that the optimal threshold value of the SS scale score for high disease activity was 31.5% with 78.3% sensitivity and 76.1% specificity (AUC: 0.802, 95% CI: 0.687-0.917, p&lt;0.001) (Figure 1). <h3>Conclusion</h3> It has been shown that the central sensitization scale, which is a simple and applicable scale, can be used to evaluate disease activity in SpA patients receiving biologic therapy. <h3>References</h3> [1]Salaffi F, et al. Early response to JAK inhibitors on central sensitization and pain catastrophizing in central sensitization rheumatoid patients with active rheumatoid arthritis. Inflammopharmacology. 2022 Jun;30(3):1119-1128. [2]Kleinert S, et al. Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis. Rheumatol Int. 2022 Nov 28. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.